Homepage Top Section1

Under the agreement, Biocodex will hold an exclusive worldwide licence to develop and commercialise Batten-1, which has been developed by THX Pharma for juvenile Batten disease (CLN3). Additionally,

The FDA accepted the gene therapy’s application under the accelerated approval pathway in May 2025. The CRL indicated that the FDA agreed in principle with the study protocol

The partnership represents the seventh agreement between the two companies and aims to expedite the delivery of new therapies to patients worldwide. Under the agreement, Innovent will utilise

The company’s fourth quarter revenues increased 1% to $12.5bn, and its growth portfolio surged 16% to $7.4bn. BMS reported non-GAAP earnings per share (EPS) of $6.15 for the

The collaboration will deploy radiology AI algorithms cleared by the US Food and Drug Administration (FDA) through Microsoft’s Precision Imaging Network, a component of its healthcare radiology solutions.

The condition has an estimated prevalence of 25,000 patients in the US and an annual incidence of one to three new cases per 100,000 people. CK0804 is an

The company’s plans are expected to increase the capacity for injectable drug products. The expansion, scheduled to commence in early 2026, will add around 300,000ft² of purpose-built space

Sobi will purchase for Arthrosi Skr9.1bn ($950m) in cash. Additional payments of up to Skr5.3bn ($550m) may be made based on clinical, regulatory and sales milestones. The acquisition

The approvals mark the fourth and fifth clearances for the company in the country in 2025. Qfitlia is the antithrombin-lowering therapy indicated for routine prophylaxis in individuals with